Ekso Bionics Holdings, Inc.

Greetings, and welcome to Exobionics' third quarter 2022 financial results call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Beth Steinberg, with FinPartners. Thank you, sir. You may begin.

Thank you, Operator, and thank you all for participating in today's call. Joining me from Exobionics are Stephen Sherman, Chairman and Chief Executive Officer, Scott Davis, President and Chief Operating Officer, and Jerome Wong, Chief Financial Officer. Earlier today, Exobionics released financial results for the third quarter of 2022. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities law, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operating expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. EXO disclaims any intention or obligation, except as required by law, to update or revise any financial or operating projections, our regulatory outlook, or other forward-looking statements, whether because of new information, future events, or otherwise, which speak only as of today, November 3, 2022. I will now turn the call over to ExoBionics Chairman and CEO, Steven Sherman.

Thank you, Matt, and thank you to everyone for joining us today. We had strong execution this quarter in all our segments. We achieved a record number of quarterly ExoNR bookings, generated several multi-unit capital purchase orders from network operators, and booked new orders internationally in both Europe and in Asia. With the recent expansion of ExoNR for MS, we're addressing patients' needs across a larger population. Overall, the growing backlog of our Exo health business gives us a solid momentum heading into the fourth quarter and into 2023. Now I'll turn the call over to Scott Davis.